Tag: dCas9-KRAB-MeCP2

IJMS | Free Full-Text | CRISPR/Cas9 Landscape: Current State and Future Perspectives

1. Introduction Genome editing has taken a leading position among genome modification technologies in a short time and is now widely used in gene therapy. To date, there are three main systems for genome editing: zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas nucleases. Genome editing has…

Continue Reading IJMS | Free Full-Text | CRISPR/Cas9 Landscape: Current State and Future Perspectives

MS Medications Added to WHO Essential List, Epigenome Therapy Shows Efficacy in AD, Phase 3 NEURO-TTransform Results Announced

WATCH TIME: 4 minutes Welcome to this special edition of Neurology News Network. I’m Marco Meglio. The World Health Organization (WHO) published new editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), which now include 3 new therapies for the treatment of multiple sclerosis….

Continue Reading MS Medications Added to WHO Essential List, Epigenome Therapy Shows Efficacy in AD, Phase 3 NEURO-TTransform Results Announced

SARS-CoV-2 restructures host chromatin architecture

Cell culture Human lung adenocarcinoma cells A549 expressing human ACE2 (A549-ACE2, NR-53821) were acquired from BEI Resources. They were maintained in DMEM/F-12 (1:1, Corning) medium supplemented with 10% FBS (GeneDepot) and blasticidin (100 μM). Normal A549 cells were purchased from ATCC (CCL-185) and cultured in DMEM/F-12 (1:1, Corning) supplemented with 10%…

Continue Reading SARS-CoV-2 restructures host chromatin architecture